Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety…
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Nave or Resistant R/M-HNSCC
Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients…
Al-Hogail Thanks the Leadership for the Council of Ministers’ Approval of the Updated Regulation for Non-Saudis’ Ownership of Real Estate
RIYADH, Saudi Arabia, July 10, 2025 /PRNewswire/ -- His Excellency Mr. Majed…
